<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRANEXAMIC ACID- tranexamic acid injection, solution </strong><br>Mylan Institutional LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_62c2fc0a-49ea-42d3-8d0e-682a721e7a70"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Antifibrinolytic agent</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_f54a6e0e-8f30-479c-beff-6c74b0dd1699"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each mL of the sterile solution for intravenous injection contains 100 mg tranexamic acid and Water for Injection to 1 mL.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5dba393-75a6-45c4-a870-786a4fe17c24"></a><a name="section-2.1"></a><p></p>
<h2>FORMULATION</h2>
<p class="First">Chemical Name: trans-4-(aminomethyl) cyclohexanecarboxylic acid.</p>
<p>Structural Formula:</p>
<div class="Figure">
<a name="id312"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6f033f1e-8c78-4c87-b870-6493944315ff&amp;name=9d2a06da-dea1-439e-97a3-41067cb102ef-01.jpg">
</div>
<p>Molecular Formula: C<span class="Sub">8</span>H<span class="Sub">15</span>NO<span class="Sub">2</span>          Molecular Weight: 157.2</p>
<p>Tranexamic acid is a white crystalline powder. The aqueous solution for injection has a pH of 6.5 to 8.0.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_6b1e8ff4-ddb9-4733-9fa6-a404b241b4e2"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Tranexamic acid is a competitive inhibitor of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent <span class="Italics">in vitro</span> than aminocaproic acid.</p>
<p>Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets <span class="Italics">in vitro</span>.</p>
<p>Tranexamic acid in concentrations as low as 1 mg per mL can prolong the <span class="product-label-link" type="condition" conceptid="4208541" conceptname="Thrombin time">thrombin time</span>. However, tranexamic acid in concentrations up to 10 mg per mL in blood showed no influence on the platelet count, the coagulation time, or other coagulation factors in whole blood or citrated blood from normal subjects.</p>
<p>The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span>. Tranexamic acid does not bind to serum albumin.</p>
<p>After an intravenous dose of 1 g, the plasma concentration time curve shows a triexponential decay with a half-life of about 2 hours for the terminal elimination phase. The initial volume of distribution is about 9 to 12 liters. Urinary excretion is the main route of elimination via glomerular filtration. Overall renal clearance is equal to overall plasma clearance (110 to 116 mL/min), and more than 95% of the dose is excreted in the urine as unchanged drug. Excretion of tranexamic acid is about 90% at 24 hours after intravenous administration of 10 mg per kg body weight.</p>
<p>An antifibrinolytic concentration of tranexamic acid remains in different tissues for about 17 hours, and in the serum, up to 7 or 8 hours.</p>
<p>Tranexamic acid passes through the placenta. The concentration in cord blood after an intravenous injection of 10 mg per kg to pregnant women is about 30 mg per liter, as high as in the maternal blood. Tranexamic acid diffuses rapidly into joint fluid and the synovial membrane. In the joint fluid, the same concentration is obtained as in the serum. The biological half-life of tranexamic acid in the joint fluid is about 3 hours.</p>
<p>The concentration of tranexamic acid in a number of other tissues is lower than in blood. In breast milk, the concentration is about one hundredth of the serum peak concentration. Tranexamic acid concentration in cerebrospinal fluid is about one tenth of that of the plasma. The drug passes into the aqueous humor, the concentration being about one tenth of the plasma concentration.</p>
<p>Tranexamic acid has been detected in semen where it inhibits fibrinolytic activity but does not influence sperm migration.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_56911c26-5973-4277-9805-c7aedb41eabc"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Tranexamic acid injection is indicated in patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> for short-term use (2 to 8 days) to reduce or prevent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and reduce the need for replacement therapy during and following tooth extraction.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_ff486099-1c6a-4437-8cb7-c84b084de140"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Tranexamic acid injection is contraindicated:</p>
<dl>
<dt>1.</dt>
<dd>In patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity (see <a href="#i4i_warnings_id_7a3eb8ff-75a5-441a-af53-494ef5047473">WARNINGS</a>).</dd>
<dt>2.</dt>
<dd>In patients with <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>. Anecdotal experience indicates that <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> and <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span> may be caused by tranexamic acid injection in such patients. </dd>
<dt>3.</dt>
<dd>In patients with active intravascular clotting.</dd>
<dt>4.</dt>
<dd>In patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tranexamic acid or any of the ingredients.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_7a3eb8ff-75a5-441a-af53-494ef5047473"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Focal areas of <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span> have developed in cats, dogs, and rats following oral or intravenous tranexamic acid at doses between 250 to 1600 mg/kg/day (6 to 40 times the recommended usual human dose) from 6 days to one year. The incidence of such lesions has varied from 25% to 100% of animals treated and was dose related. At lower doses, some lesions have appeared to be reversible.</p>
<p>Limited data in cats and rabbits showed retinal changes in some animals with doses as low as 126 mg/kg/day (only about 3 times the recommended human dose) administered for several days to 2 weeks.</p>
<p>No retinal changes have been reported or noted in eye examinations in patients treated with tranexamic acid for weeks to months in clinical trials.</p>
<p>However, visual abnormalities, often poorly characterized, represent the most frequently reported post-marketing adverse reaction in Sweden. For patients who are to be treated continually for longer than several days, an ophthalmological examination, including visual acuity, color vision, eye-ground, and visual fields, is advised, before commencing and at regular intervals during the course of treatment. Tranexamic acid should be discontinued if changes in examination results are found.</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_0fd342b3-4ff4-4dbc-bba5-c4bcb7cc8660"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_fc34cb7f-2d68-4c0e-af23-efce57c7c99c"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The dose of tranexamic acid injection should be reduced in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> because of the risk of accumulation. (See <a href="#i4i_dosage_admin_id_257994f8-c74f-4ff2-bd9e-65816837a7bd">DOSAGE AND ADMINISTRATION</a>.)</p>
<p>Ureteral obstruction due to clot formation in patients with upper urinary tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> has been reported in patients treated with tranexamic acid injection.</p>
<p>Venous and <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span> or <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> has been reported in patients treated with tranexamic acid injection. In addition, cases of central retinal artery and central retinal vein obstruction have been reported.</p>
<p>Patients with a previous history of thromboembolic disease may be at increased risk for venous or <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>.</p>
<p>Tranexamic acid injection should not be administered concomitantly with Factor IX Complex concentrates or Anti-inhibitor Coagulant concentrates, as the risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> may be increased.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> (DIC), who require treatment with tranexamic acid injection, must be under strict supervision of a physician experienced in treating this disorder.</p>
<p>Tranexamic acid may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and therefore may influence the ability to drive or use machines.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_61e5988f-365b-4341-acdf-9de6037e06e9"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions </h2>
<p class="First">No studies of interactions between tranexamic acid injection and other drugs have been conducted.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_79fcc089-0778-4dda-a266-f1bc2a863fc2"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">An increased incidence of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> in male mice receiving tranexamic acid in food at a concentration of 4.8% (equivalent to doses as high as 5 g/kg/day) may have been related to treatment. Female mice were not included in this experiment.</p>
<p><span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">Hyperplasia</span> of the biliary tract and cholangioma and adenocarcinoma of the intrahepatic biliary system have been reported in one <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rats after dietary administration of doses exceeding the maximum tolerated dose for 22 months. Hyperplastic, but not neoplastic, lesions were reported at lower doses. Subsequent long-term dietary administration studies in a different <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rat, each with an exposure level equal to the maximum level employed in the earlier experiment, have failed to show such hyperplastic/neoplastic changes in the liver. No mutagenic activity has been demonstrated in several <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> test systems.</p>
<p> There are no clinical data to assess the effects of tranexamic acid on fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_6458e3e7-30e6-4562-92d2-81724d003318"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy (Category B)</h2>
<p class="First">Reproduction studies performed in mice, rats, and rabbits have not revealed any evidence of impaired fertility or adverse effects on the fetus due to tranexamic acid.</p>
<p>There are no adequate and well controlled studies in pregnant women. However, tranexamic acid is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_fb4cb37a-3f08-4100-a696-a4d2ea4f93d2"></a><a name="section-7.5"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">See above under <a href="#i4i_pregnancy_id_6458e3e7-30e6-4562-92d2-81724d003318">Pregnancy</a>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_72ac6b54-5260-4af1-b781-d8d8d2e177b3"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Tranexamic acid is present in the mother's milk at a concentration of about a hundredth of the corresponding serum levels. Caution should be exercised when tranexamic acid injection is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_e43df978-0580-40b9-9de2-4bbd40d71af6"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The drug has had limited use in pediatric patients, principally in connection with tooth extraction. The limited data suggest that dosing instructions for adults can be used for pediatric patients needing tranexamic acid injection therapy.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_ed9aea6b-afa4-4891-8114-73f9e494b07f"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of tranexamic acid injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <a href="#i4i_clinical_pharmacology_id_6b1e8ff4-ddb9-4733-9fa6-a404b241b4e2">CLINICAL PHARMACOLOGY</a> and <a href="#i4i_dosage_admin_id_257994f8-c74f-4ff2-bd9e-65816837a7bd">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_118cf0cc-0ff5-4b93-9961-e23b170bbb30"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disturbances</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>) may occur but disappear when the dosage is reduced. <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Allergic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">giddiness</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> have been reported occasionally. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> has been observed when intravenous injection is too rapid. To avoid this response, the solution should not be injected more rapidly than 1 mL per minute.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_26eaa7c7-a3b4-46f6-92a6-54c3f463661f"></a><a name="section-8.1"></a><p></p>
<h2>Worldwide Post-Marketing Reports </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic events</span> (e.g., <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">cerebral thrombosis</span>, acute <span class="product-label-link" type="condition" conceptid="40480627" conceptname="Renal cortical necrosis">renal cortical necrosis</span>, and central retinal artery and vein obstruction) have been rarely reported in patients receiving tranexamic acid for indications other than <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> prevention in patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span>, <span class="product-label-link" type="condition" conceptid="4092111" conceptname="Chromatopsia">chromatopsia</span>, and <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span> have also been reported. However, due to the spontaneous nature of the reporting of medical events and the lack of controls, the actual incidence and causal relationship of drug and event cannot be determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_5b097308-a55b-4324-95fb-b0ba1d64219d"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Cases of overdosage of tranexamic acid have been reported. Based on these reports, symptoms of overdosage may be gastrointestinal, e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; hypotensive, e.g., orthostatic symptoms; thromboembolic, e.g., arterial, venous, embolic; neurologic, e.g., <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>; <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_257994f8-c74f-4ff2-bd9e-65816837a7bd"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Immediately before tooth extraction in patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>, administer 10 mg per kg body weight of tranexamic acid injection intravenously together with replacement therapy (see <a href="#i4i_precautions_id_0fd342b3-4ff4-4dbc-bba5-c4bcb7cc8660">PRECAUTIONS</a>). Following tooth extraction, intravenous therapy, at a dose of 10 mg per kg body weight 3 to 4 times daily, may be used for 2 to 8 days.</p>
<p><span class="Italics">Note:</span> For patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, the following dosages are recommended:</p>
<table>
<col width="32%">
<col width="31%">
<thead><tr class="First Last">
<th class="Botrule Toprule"><span class="Bold">Serum Creatinine (µmol/L)</span></th>
<th class="Botrule Toprule"><span class="Bold">Tranexamic Acid I.V. Dosage</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" valign="top"><p class="First">120 to 250 (1.36 to 2.83 mg/dL)</p></td>
<td class="Toprule" valign="top"><p class="First">10 mg/kg BID</p></td>
</tr>
<tr>
<td valign="top"><p class="First">250 to 500 (2.83 to 5.66 mg/dL)</p></td>
<td valign="top"><p class="First">10 mg/kg daily</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">&gt; 500 (&gt; 5.66 mg/dL)</p></td>
<td class="Botrule" valign="top"><p class="First">10 mg/kg every 48 hours<br>             or<br>5 mg/kg every 24 hours</p></td>
</tr>
</tbody>
</table>
<p>For intravenous infusion, tranexamic acid injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions. The mixture should be prepared the same day the solution is to be used. Heparin may be added to tranexamic acid injection. Tranexamic acid injection should NOT be mixed with blood. The drug is a synthetic amino acid, and should NOT be mixed with solutions containing penicillin.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_2a754d52-6dea-4a44-a66c-39cab4355bbd"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Tranexamic Acid Injection 1000 mg/10 mL (100 mg/mL), a clear, colorless solution, is available in:</p>
<p><span class="Bold">Mylan Institutional LLC</span><br>NDC 67457-197-10<br>10 mL single-dose vial, packages of 10</p>
<p><span class="Bold">NOVAPLUS®</span><br>NDC 67457-293-10<br>10 mL single-dose vial, packages of 10</p>
<p>N+ and NOVAPLUS are registered trademarks of Novation, LLC.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled</span><br><span class="Bold">Room Temperature.]</span></p>
<p>Sterile, Non-pyrogenic.</p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>REVISED MAY 2013<br>MI:TREXIJ:R4</p>
<p>0784L103<br><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_4ee1cd6e-d250-441d-8703-0b5c4d5c1de3"></a><a name="section-12"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1000 mg/10 mL</span></p>
<p><span class="Bold">NDC 67457-197-10</span></p>
<p><span class="Bold">Tranexamic Acid</span><br><span class="Bold">Injection</span></p>
<p><span class="Bold">1000 mg/10 mL</span><br>(100 mg/mL)</p>
<p><span class="Bold">For Intravenous Use Only</span></p>
<p><span class="Bold">Rx only   10 x 10 mL Single-Dose Vials</span></p>
<p>Sterile. Non-pyrogenic.</p>
<p>Discard unused portion.</p>
<p><span class="Bold">Each mL contains:</span><br>Tranexamic acid, 100 mg; water for<br>injection, q.s.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>MI:197:10C:R2</p>
<p><span class="Bold">Mylan.com</span></p>
<div class="Figure">
<a name="id591"></a><img alt="Tranexamic Acid Injection 1000 mg/10 mL Carton Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6f033f1e-8c78-4c87-b870-6493944315ff&amp;name=9d2a06da-dea1-439e-97a3-41067cb102ef-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_413f1313-adce-4163-bc04-1fc6f7e8941a"></a><a name="section-13"></a><p></p>
<h1>       </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1000 mg per 10 mL</span></p>
<p><span class="Bold">NDC 67457-293-10     Rx only</span></p>
<p><span class="Bold">Tranexamic Acid</span><br><span class="Bold">Injection</span></p>
<p><span class="Bold">For Intravenous Use Only</span><br><span class="Bold">10 x 10 mL Single-Dose Vials</span></p>
<p><span class="Bold">1000 mg per 10 mL</span><br>(100 mg per mL)</p>
<p>N+ and NOVAPLUS are registered trademarks of Novation, LLC.</p>
<p>NOVAPLUS<span class="Sup">®</span></p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p>Sterile, Nonpyrogenic<br>Discard unused portion.</p>
<p><span class="Bold">Each mL contains:</span><br>Tranexamic acid, 100 mg; water<br>for injection, q.s.</p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Made in Ireland</p>
<p>MI:293:10C:R2</p>
<div class="Figure">
<a name="id29835416"></a><img alt="Tranexamic Acid Injection 1000 mg/10mL Carton - Novaplus" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6f033f1e-8c78-4c87-b870-6493944315ff&amp;name=9d2a06da-dea1-439e-97a3-41067cb102ef-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRANEXAMIC ACID 		
					</strong><br><span class="contentTableReg">tranexamic acid injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-197</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRANEXAMIC ACID</strong> (TRANEXAMIC ACID) </td>
<td class="formItem">TRANEXAMIC ACID</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-197-10</td>
<td class="formItem">10  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-197-00</td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091657</td>
<td class="formItem">11/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRANEXAMIC ACID 		
					</strong><br><span class="contentTableReg">tranexamic acid injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-293</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRANEXAMIC ACID</strong> (TRANEXAMIC ACID) </td>
<td class="formItem">TRANEXAMIC ACID</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-293-10</td>
<td class="formItem">10  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-293-00</td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091657</td>
<td class="formItem">11/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional LLC
							(790384502)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9d2a06da-dea1-439e-97a3-41067cb102ef</div>
<div>Set id: 6f033f1e-8c78-4c87-b870-6493944315ff</div>
<div>Version: 8</div>
<div>Effective Time: 20130525</div>
</div>
</div> <div class="DistributorName">Mylan Institutional LLC</div></p>
</body></html>
